TickerGuard
Buy Day today: Neutral (56) Mixed market breadth · major macro event coming up
SLS

Sellas Life Sciences Group Inc

Healthcare · Biotechnology · —

11.60$ -3.1% vs. previous close Closing price · As of: Sep 25, 2026

Statements

Cash Flow

All figures per share in USD.

Tick rows to compare them in a chart (up to 4)

Cash Flow SLS
Line item 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
-558.73 -1,592.15 -2,287.48 -2,421.60 -1,862.20 -1,345.81 -1,118.74 -1,068.53 -1,197.09 -2,408.00 -135.31 -234.77 -116.32 -6.90 -1.31 -1.68 -1.23 -1.13 -0.58 -0.26
– 9.48 31.78 33.33 31.23 14.96 2.62 16.71 24.82 17.75 0.43 0.00 14.37 0.66 0.04 0.37 0.02 – – –
– – 927.70 864.61 793.03 275.35 74.39 93.52 150.43 96.55 6.82 67.70 1.51 0.22 0.07 0.07 0.09 0.05 0.03 0.02
– – – – – 282.69 37.68 -4.36 156.01 -353.10 -27.65 137.63 28.86 1.29 0.09 0.15 0.61 – – –
-47.88 177.46 -1.21 58.64 56.64 234.43 5.66 92.74 111.33 993.65 -75.06 129.57 -38.26 -0.43 0.70 -0.49 0.29 0.12 -0.11 -0.04
0.00 60.29 40.27 17.08 19.24 4.86 39.44 585.79 154.37 7.65 0.02 0.00 0.00 0.00 0.00 0.00 0.23 0.20 0.00 0.00
– -2,639.55 2,328.97 -17.08 -19.24 1.28 -4.64 -444.89 -154.37 519.75 -3.18 38.71 – -1.76 -0.56 -0.29 -0.23 -0.20 – –
– – – – 84.24 0.00 0.00 0.00 0.00 24.35 1.47 14.42 1.86 0.00 – – – – – –
– – – – -698.80 1,721.72 2,232.95 1,697.38 719.42 2,372.35 102.51 10.11 119.33 7.65 4.78 – – 0.00 – –
– – – – – -7.71 -0.53 363.72 -49.31 -195.55 53.69 -10.11 -29.06 – – – – – – –
558.73 4,695.37 1,921.88 1,580.25 2,100.58 1,761.26 2,264.06 2,067.13 677.45 2,192.25 103.40 118.23 88.41 7.65 4.82 0.78 1.24 0.80 0.76 0.79
558.73 463.67 1,963.37 -858.44 219.14 416.74 1,140.68 553.71 -674.01 304.00 -35.09 -77.83 -27.91 0.75 3.51 -0.90 -0.22 -0.53 0.19 0.53
-558.73 -1,652.45 -2,327.75 -2,438.68 -1,881.45 -1,350.67 -1,118.74 -1,654.32 -1,351.46 -2,415.65 -135.32 -234.77 -116.32 -6.90 -1.31 -1.68 -1.46 -1.33 -0.58 -0.26

Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?